<--- Back to Details
First PageDocument Content
Steelmaking / Chemistry / Business / Economy / Peaslee / Continuous casting / Electric arc furnace / Ladle / Refractory / Casting / Investment casting / Basic oxygen steelmaking
Date: 2014-01-22 04:01:43
Steelmaking
Chemistry
Business
Economy
Peaslee
Continuous casting
Electric arc furnace
Ladle
Refractory
Casting
Investment casting
Basic oxygen steelmaking

SELECTED PUBLICATIONS AND RESEARCH PROJECTS BY MISSOURI S&T STEEL CENTER FACULTY Below are a selected sampling of work performed by the Steel Center faculty members at Missouri S&T. All entries are listed by these catego

Add to Reading List

Source URL: mse.mst.edu

Download Document from Source Website

File Size: 324,15 KB

Share Document on Facebook

Similar Documents

小児骨髄異形成症候群の病態に関与するゲノム基盤の同定 東京大学医学部附属病院 無菌治療部 講師 加藤 元博 【背 景】  小児不応性血球減少症(Refractory

小児骨髄異形成症候群の病態に関与するゲノム基盤の同定 東京大学医学部附属病院 無菌治療部 講師 加藤 元博 【背 景】  小児不応性血球減少症(Refractory

DocID: 1veBA - View Document

Zampell Completes Refractory Installation  Z ampell Refractories, Inc. successfully completed the

Zampell Completes Refractory Installation Z ampell Refractories, Inc. successfully completed the

DocID: 1uKSw - View Document

A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan

A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan

DocID: 1uJQ2 - View Document

GMI-1271, a Potent E-Selectin Antagonist, in Combination with Chemotherapy in Relapsed/Refractory AML: A Novel, Well-Tolerated Regimen with a High Remission Rate Daniel J. DeAngelo*1, Brian A. Jonas2, Jane L. Liesveld3,

GMI-1271, a Potent E-Selectin Antagonist, in Combination with Chemotherapy in Relapsed/Refractory AML: A Novel, Well-Tolerated Regimen with a High Remission Rate Daniel J. DeAngelo*1, Brian A. Jonas2, Jane L. Liesveld3,

DocID: 1uIxU - View Document

Case Study Newsletter 11_Overactive Bladder_Richter.qxp_Layout:03 PM Page 1  Advancing Health A CASE STUDY from MedStar Washington Hospital Center  Treating Refractory Overactive Bladder:

Case Study Newsletter 11_Overactive Bladder_Richter.qxp_Layout:03 PM Page 1 Advancing Health A CASE STUDY from MedStar Washington Hospital Center Treating Refractory Overactive Bladder:

DocID: 1sUu3 - View Document